Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 3, Number 2—June 1997

Synopsis

Borna Disease

Carolyn G. Hatalski, Ann J. Lewis, and W. Ian LipkinComments to Author 
Author affiliations: University of California, Irvine, California, USA

Main Article

Table 1

Serum immunoreactivity to Borna disease virus in various diseases

Prevalence
Disease Disease (%) Controls (%) Assay Ref.
Psychiatric (4/694) 0.6 (0/200) 0 IFA (36)
(various) (13/642) 2 (11/540) 2 IFA (60)
(200-350/5000) 4-7 (10/1000) 1 WB IFA / (61)
(18/60) 30 (1/100) 1 WB (24, 25)
(18/132) 13.6 (3/203) 1.5 WB (27)
(13/55) 23.6 (4/36) 11.1 IFA (51)
(6/49) 12.2 IFA (38)
Affective (12/265) 4.5 (0/105) 0 IFA (62)
(12/285) 4.2 (0/200) 0 IFA (36)
(53/138) 38 (19/117) 16 WB (37)
(6/52) 11.5 (3/203) 1.4 WB (27)
(10/27) 37 IFA (38)
Schizophrenia (29/90) 32 (4/20) 20 WB (43)
(16/114) 14 (3/203) 1.5 WB (27)
(1/4) 25 IFA (38)
CFS (6/25) 24 WB (26)
MS (15/114) 13 (10/483) 2.1 IP/ IFA (63)
HIV-positive (36/460) 7.8 (11/540) 2 IFA (60)
HIV-early (61/751) 8.1 (10/483) 2 IP/ IFA (61)
HIV-LAP (34/244) 14 (10/483) 2 IP/ IFA (63)
Schisto/malaria (19/193) 9.8 (10/483) 2 IP/IFA (63)

Abbreviations: IFA, immunofluorescence assay; WB, Western immunoblot; IP, immunoprecipitation; CFS, chronic fatigue syndrome; MS, multiple sclerosis; HIV, human immunodeficiency virus; LAP, lymphadenopathy; Schisto/malaria, schistosomiasis or malaria.

Main Article

TOP